The SURPASS-CVOT trial is specifically evaluating tirzepatide cardiovascular outcomes
has received grant funding and acted as a consultant for Metsera Inc
The aim of the How to series is to provide readers with a guide to clinical procedures and aspects of diabetes care that are covered in the clinic setting
Individuals have been losing significant weight at Prevention Clinics with these medications, However, a growing concern among providers and the general public is the potential for muscle loss alongside fat loss
Nonetheless, reports of unplanned pregnancies have increased as more reproductive-aged individuals use these agents, underscoring their ability to restore normal ovulatory cycles once metabolic conditions improve
In public statements following the filing, Hims called the lawsuit "a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care." Novo challenged the efficacy of Hims's oral formulation and cited its own testing of compounded semaglutide products, reporting impurity levels of up to 86% in injectable formulations and up to 75% in oral formulations
